There is one clinical trial.

Clinical Trials

1 Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)

Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit. Control intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias. Duration of intervention per patient: varies, depending on severity of pulmonary compromise Follow-up per patient: Until hospital discharge Accompanying measures: Serum Samples and bronchoscopy samples of patients included into the trial for secondary analysis of inflammatory parameters and potential biomarkers

NCT04341285 ARDS, Human COVID-19 Procedure: ECMO Implantation

MeSH:Respiratory Distress Syndrome, Adult

No related HPO nodes (Using clinical trials)